

**Client:** Chi Med  
**Source:** Dow Jones  
**Date:** 22 February 2012

---

**DJ Hutchison China's Volitinib Phase 1 Trial Initiated**

**DJ Hutchison China's Volitinib Phase 1 Trial Initiated**

LONDON (Dow Jones)--Hutchison China Meditech Ltd (HCM.LN), the holding company of a pharmaceutical and healthcare group mainly based in China, said Wednesday that its majority owned Hutchison MediPharma Limited, a research and development group, has announced the initiation of the first-in-human Phase I clinical trial of cancer treatment Volitinib, HMPL-504, in Australia.

**MAIN FACTS:**

- Volitinib is a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer.
- Phase I study of Volitinib has been approved by the Bellberry Human Research Ethics Committee in Australia.
- Primary objectives of the Phase I study of Volitinib are to evaluate its safety and tolerability in patients with advanced cancer and to determine its maximum tolerated dose.
- Shares at 0803 GMT unchanged at 460 pence valuing the company at GBP238.25 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Order free Annual Report for Hutchison China MediTech Ltd

Visit <http://djnweurope.ar.wilink.com/?ticker=KYG4672N1016> or call +44 (0)208 391 6028

(END) Dow Jones Newswires

February 22, 2012 03:04 ET (08:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.